(Q87424383)

English

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer

scientific article published on 12 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

fallopian tube cancer

1 reference

based on heuristic

inferred from title

fallopian tube carcinoma

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Anita Schwandt

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Vivian E von Gruenigen

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Robert M Wenham

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Heidi Frasure

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Susan Eaton

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Nancy Fusco

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

John J Wright

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Afshin Dowlati

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Steven Waggoner

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

12 March 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

729-738

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations of the BRAF gene in human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Point mutation of the ras oncogene in human ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24619298

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-014-0078-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24619298%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87424383&oldid=1622273092"